Novartis receives two new FDA approvals for Cosentyx® (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis

Novartis receives two new FDA approvals for Cosentyx® (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis

Jan 15, 2016
Source URL: https://qa1.novartis.us/us-en/news/media-releases/novartis-receives-two-new-fda-approvals-cosentyx-secukinumab-treat-patients-ankylosing-spondylitis-and-psoriatic-arthritis-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-receives-two-new-fda-approvals-cosentyx-secukinumab-treat-patients-ankylosing-spondylitis-and-psoriatic-arthritis-0